Markets:

Overview

News

Currencies

International

Treasuries

iShares U.S. Healthcare ETF (NY:IYH)

62.69 +0.04 (+0.06%)

Streaming Delayed Price Updated: 11:38 AM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about iShares U.S. Healthcare ETF

< Previous 1 2 3 Next >

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗

February 26, 2026

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

Via Stocktwits

Topics Artificial Intelligence

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗

February 26, 2026

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’.

Via Stocktwits

Topics Artificial Intelligence

Why Did IXHL Stock Tank Over 32% Today? ↗

February 25, 2026

The company’s board approved a 1-for-30 reverse stock split, effective on February 26.

Via Stocktwits

Why Did GERN Stock Tumble 10% Pre-Market Today? ↗

February 25, 2026

Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates.

Via Stocktwits

Topics Artificial Intelligence

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗

January 22, 2026

Via Stocktwits

FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report ↗

October 31, 2025

Via Stocktwits

Trump Says He's 'Happy To Work' With Democrats On 'Failed' Healthcare Policies, But Calls To End Government Shutdown ↗

October 06, 2025

Via Stocktwits

Topics Government

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? ↗

February 24, 2026

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

Via Stocktwits

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗

February 24, 2026

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

Via Stocktwits

Why Did IOVA Stock Gain Pre-Market Today? ↗

February 24, 2026

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.

Via Stocktwits

Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗

February 23, 2026

According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.

Via Stocktwits

Topics Intellectual Property

Retail Traders Evenly Split About Government Shutdown Odds: Strategists Weigh In On Whether Jobs Report Would Be Delayed Amid Looming Risk ↗

September 29, 2025

Via Stocktwits

Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗

February 20, 2026

Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating.

Via Stocktwits

Why Did IMUX Stock Surge 33% Pre-Market Today? ↗

February 13, 2026

Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs.

Via Stocktwits

Why Did Healthcare Triangle Stock Plummet 20% Today? ↗

February 06, 2026

The technology firm announced that it will implement a 1-for-60 reverse stock split of its common shares effective at 12:01 a.m. Eastern Time on February 10.

Via Stocktwits

Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗

January 22, 2026

In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.

Via Stocktwits

Monster Beverage, UnitedHealth, Thermo Fisher Scientific And More: CNBC's 'Final Trades' ↗

November 18, 2025

Today's "Final Trades" segment focused on UnitedHealth, Thermo Fisher Scientific, iShares U.S. Healthcare ETF and Monster Beverage.

Via Benzinga

Topics ETFs

Why Is Co-Diagnostics Stock Sinking Tuesday? ↗

October 28, 2025

Co-Diagnostics (CODX) stock falls over 50% as they announced a $7 million offering and Saudi joint venture, causing concerns about dilution.

Via Benzinga

Wellgistics And DataVault Team Up To Transform Prescription Tracking ↗

October 22, 2025

DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.

Via Benzinga

Topics Artificial Intelligence

Premier Set For Private Ownership, Eyes Growth Push ↗

September 22, 2025

Premier Inc. to be acquired by Patient Square Capital at $28.25 per share, offering shareholders a 23.8% premium.

Via Benzinga

As the Market Rotates, This Healthcare ETF Is Leading the Way ↗

August 26, 2025

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

Via MarketBeat

Topics ETFs

Brace For Higher Healthcare Premiums In 2026 As Insurers Blame Trump's Tariffs In Filings To Regulators: Report ↗

June 19, 2025

Health insurance companies have raised concerns that tariffs could lead to higher premiums for enrollees in the individual and small group markets next year.

Via Benzinga

Topics Government World Trade

Omada Health Prices $150M IPO In-Line With Estimated Range ↗

June 06, 2025

Omada Health (OMDA) priced its IPO at $19 per share, midpoint of the previously estimated price range of $18.00 and $20.00 per share

Via Stocktwits

Topics Initial Public Offering

Guardian Pharmacy Strengthens US Footprint With New Seattle-Area Acquisition ↗

June 02, 2025

Guardian Pharmacy Services acquires Mercury Pharmacy Services in Washington, expanding its presence in the Pacific Northwest and meeting growing demand for LTC support.

Via Benzinga

Tariffs Bite Dan Loeb's Portfolio: Thermo Fisher Hit Hard, Discover Shines ↗

April 28, 2025

Year to date, Thermo Fisher fell about 21.03%, both underperforming the iShares U.S. Healthcare ETF, which declined about 2.36%.

Via Benzinga

Topics ETFs

Healthcare Sector Trying To Bounce Back ↗

March 09, 2025

I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector.

Via Talk Markets

Topics ETFs Stocks / Equities

Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars? ↗

March 04, 2025

Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as...

Via Talk Markets

Topics ETFs Stocks / Equities

Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor ↗

February 25, 2025

Loeb's Third Point LLC restructured their portfolio in last quarter of 2024. They decreased stake in Danaher Corp. and acquired stake in Thermo Fisher.

Via Benzinga

NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst ↗

February 24, 2025

Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.

Via Benzinga

Spotify, Vertiv Holdings And More: CNBC's 'Final Trades' ↗

February 13, 2025

Joseph M. Terranova picked Spotify Technology, which reported better-than-expected fiscal fourth-quarter 2024 financial sales.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.